Evogene opened lower at $0.36, compared with its previous close of $0.40. In the last trading session, the stock traded between $0.35 and $0.37. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Evogene is now worth
$ 1.43
Resulting in a loss of
$ 98.57 (98.57%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.03 (-7.69%)
Day High
$0.37
Day Low
$0.35
Day Open
$0.36
Prev Close
$0.40
Volume
47,592
1W Return
-2.67%
1M Return
-6.89%
3M Return
-47.71%
6M Return
-53.02%
1Y Return
-70.56%
Market Cap ($ Mn)
7
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-70.44%
EPS (TTM)
$-0.13
1 Week
-2.67%
1 Month
-6.89%
3 Months
-47.71%
6 Months
-53.02%
9 Months
-64.22%
Evogene targets acute graft-versus-host disease for drug discovery
Evogene selects acute graft-versus-host disease (aGVHD) as target indication. Focuses on developing first-in-class small-molecule therapeutic. Targets multi-billion-dollar market for steroid-refractory patients. Utilizes AI-driven generative design platform for drug discovery.
15 days agoEvogene resolves board dispute with Pure Capital Group agreement
Evogene and Pure Capital Group reach agreement to resolve corporate differences. Four Pure Capital nominees will join the seven-member board post-approval. Special tender offer notice withdrawn with 60-day standstill period imposed.
1mo agoEvogene gets Nasdaq extension to March 29, 2027, for bid price compliance
Nasdaq grants Evogene an additional 180-day period until March 29, 2027, to regain compliance with minimum bid price rules. Compliance requires a closing bid price of at least $1.00 for ten consecutive business days. Initial non-compliance notice was issued on March 30, 2026, due to bid prices falling below $1.00. Evogene may consider a reverse share split to cure the deficiency if market conditions do not improve. Listing on the Tel Aviv Stock Exchange remains unaffected by the Nasdaq notice.
1mo agoEvogene cites cash burn cut, new deals to counter dissident board push
Evogene urges shareholders to vote for its board nominees against dissident proposals. Annual cash burn expected to fall from ~$20.5 million in 2024 to $8.5–$9.5 million in 2026. Company signed six drug-development agreements and reduced headcount from 117 to 38. Lavie Bio was sold to ICL for approximately $15.25 million. Dissidents rejected a compromise to add one director, demanding full board replacement.
2mo agoEvogene Q2 EPS $(0.13) beats estimate, sales fall 61% YoY
Evogene (NASDAQ: EVGN) reported Q2 EPS of $(0.13), beating the $(0.27) consensus by 51.85%. Sales of $347,000 also beat estimates but fell 60.75% YoY from $884,000. The company continues to face margin pressure despite top-line beats.
2mo agoAgPlenus launches Antifungal Potency Predictor using machine learning
AgPlenus Ltd., a subsidiary of Evogene Ltd., has launched its Antifungal Potency Predictor (APP), a machine learning model that predicts antifungal potency from chemical structures. The APP enhances Evogene's ChemPass AI for Ag™ platform by forecasting biological efficacy before synthesis and assay validation, streamlining crop protection product development.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Evogene is now worth
$ 1.43
Resulting in a loss of
$ 98.57 (98.57%)
Note: Past profits do not guarantee future returns.
